keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
Published 5 years ago • 417 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
6:58
keynote-426 study
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
0:58
michael atkins, md, regarding the keynote 426 phase iii trial in metastatic renal cell carcinoma
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
1:04
tian zhang, md, elaborates on the outcomes of keynote 426 presented at gu 2019
-
2:16
updated results from keynote-426 for metastatic kidney cancer
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:46
researcher comment: updated keynote-426 data | elizabeth plimack